Home›Companies›Biotech & Pharma›Chimeron Bio

Chimeron Bio Corp

Updated Oct 27, 2026·Latest SEC filing Mar 14, 2025·Suggest an edit

About Chimeron Bio

Chimeron Bio is a private company based in Philadelphia, Pennsylvania. It has reported $15,093,690 raised in four offerings on Form D since December 2020. Its chief executive is Kevin Heyeck.

Funding Rounds (SEC Form D)

First saleFiled with SECAmount soldInvestorsAvg. checkTermsFiling
Mar 25, 2024Mar 3, 2025amended Mar 14, 2025$12,811,690target not set9$1.4MEquityRule 506(b)Form D/A ↗1 earlier filing
Oct 31, 2022Nov 30, 2022$1,200,000of $10.0M target3$400KDebt, Convertible Promissory NotesRule 506(b)Form D ↗
Feb 28, 2022Mar 10, 2022$782,000of $3.0M target1$782KDebt, Convertible Promissory NotesRule 506(b)Form D ↗
Dec 9, 2020Dec 28, 2020$300,000of $5.0M target2$150KEquityRule 506(b)Form D ↗
Total, four offerings$15,093,690

First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.

Leadership Team

Executive officers and directors listed on Chimeron Bio's Form D filed Mar 14, 2025.

MC
Monica Coleman
Executive officer
KH
Kevin Heyeck
Chief Executive Officer and director
AS

Earlier filings also listed Thimmaiah Chendrimada (executive officer, last listed Nov 2022), Gorka Fius (director, last listed Nov 2022), Jolly Mazmudar (executive officer and director, last listed Mar 2022), Hemanshu Pandya (director, last listed Mar 2022) and Chiraag Patel (director, last listed Mar 2022).

Sources

  1. SECChimeron Bio Corp Form D, filed Mar 3, 2025
  2. SECChimeron Bio Corp filing history